Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adobe

Burlington Stores

O'Reilly Automotive

TriNet Group

The Dow Jones dipped about 40 points, and the S&P 500 was flat. Meanwhile, the Nasdaq continued mild gains.

Adobe Inc Ranked Among Today's Top Buys Amid Lower-Than-Expected Jobless Claims

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Waters (WAT) Up 5.6% Since Last Earnings Report: Can It Continue?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will present at the Bank of America Global Healthcare Conference 2021 virtually on Thursday, September 16th, 2021 at 3:55PM BST (UTC+1) / 10:55AM Eastern Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty

Waters to Present at the Bank of America Global Healthcare Conference 2021

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Morgan Stanley's 19th Annual Global Healthcare on Tuesday, September 14th, 2021 at 8:45AM Eastern Standard Time. Interested investors can access the live webcast of the presentation on Waters' investor relations website at https://ir.waters.com . About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty

Waters to Participate in a Virtual Fireside Chat at Morgan Stanley's 19th Annual Global Healthcare Conference

Does Waters (WAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Waters (WAT) is a Great Momentum Stock: Should You Buy?

Waters (WAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Waters (WAT) Run Higher on Rising Earnings Estimates?

Waters Corporation's (WAT) CEO Udit Batra on Q2 2021 Results - Earnings Call Transcript

Waters' (WAT) second-quarter results reflect gains from strong momentum across pharmaceutical, industrial, and governmental and academic markets.

Waters (WAT) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y

Shares of Waters (NYSE:WAT) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 23.81% over the past year to $2.60, which beat the estimate of $2.24.

Waters: Q2 Earnings Insights

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced second quarter 2021 sales of $682 million, a 31% increase as reported, compared to sales of $520 million for the second quarter of 2020. Foreign currency translation benefited sales growth by approximately 4% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the second quarter of 2021 increased to $2.69, compared to $1.98 for the second quarter of 2020. On a non-GAAP basis, EPS increased to $2.6

Waters Corporation (NYSE: WAT) Reports Second Quarter 2021 Financial Results

Waters' (WAT) second-quarter 2021 results are likely to reflect strength across liquid chromatography instruments and mass spectrometers.

Waters (WAT) to Report Q2 Earnings: What's in the Cards?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Waters (WAT) is a Top Momentum Stock for the Long-Term

Invesco S&P Global Water Index ETF

Danaher

First Trust Water ETF

Invesco Water Resources ETF

Roper Technologies

Water sustainability is a growing concern for many investors

Here's Why You Should Invest in Water ETFs

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q2 2021 financial results conference call live on Tuesday August 3rd, 2021 at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters' website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until August 10th, 2021 at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty measurement

Waters Corporation Q2 2021 Financial Results Webcast Invitation

Waters (WAT) strengthens the product portfolio by introducing TRIOS AutoPilot software for the thermal analyzer product line.

Waters (WAT) Boosts Thermal Analysis With Latest Software

NEW CASTLE, Del.--(BUSINESS WIRE)---- $WAT #thermalanalysis--TRIOS AutoPilot software is now available for the TA Instruments thermal analysis product line.

TA Instruments Helps Laboratories Automate Thermal Analysis Workflows with New TRIOS AutoPilot Software

MILFORD, Mass. & SINGAPORE--(BUSINESS WIRE)---- $WAT #bioinformatics--Waters expands collaboration with Singapore's Bioprocessing Technology Institute, A*STAR to accelerate bioprocessing and bioinformatics research.

Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore's Bioprocessing Technology Institute

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corp. will appoint Wei Jiang, EVP and President of APAC and China at Bayer Pharmaceuticals, to the Waters Board of Directors.

Waters Corporation Appoints Wei Jiang to Board of Directors

Waters (WAT) expands the product portfolio by introducing Arc Premier System for chromatographic separations.

Waters (WAT) Expands Reach to Scientists Via Latest Launch

MILFORD, Mass.--(BUSINESS WIRE)-- #UHPLC--The Waters Arc Premier System with MaxPeak HPS technology is optimized for chromatographic separations on 2.5 – 3.5 micron MaxPeak Premier Columns.

Waters Arc Premier System Delivers Increased Precision and Certainty in Chromatographic Results

MILFORD, Mass.--(BUSINESS WIRE)-- #imagingmassspec--Waters Sets New Standard in High Resolution Mass Spectrometry with the Introduction of the SELECT SERIES Multi Reflecting Time-of-Flight Platform

Waters Sets New Standard in High Resolution Mass Spectrometry with SELECT SERIES Multi Reflecting Time-of-Flight Platform

Why Is Waters (WAT) Up 2.4% Since Last Earnings Report?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results. “For biomedical and clinical research laboratories that are involved in fighting the pandemic, this kit offers a

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation Celebrates the Life and Legacy of its Founder, Jim Waters

Waters Corporation Celebrates the Life and Legacy of its Founder, Jim Waters

FRAMINGHAM, Mass. & MILFORD, Mass.--(BUSINESS WIRE)--SCIEX and Waters Corporation collaborate to deliver fully configured and interoperable LC-MS systems

News for Waters Stock (WAT)